|
|
|
January 2012Gilead acquires Princeton, New Jersey-based Pharmasset.
August 2011
|
|
U.S. Food and Drug Administration Approves Gilead Sciences’ Complera™, a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Naïve Adults |
April 2011Gilead acquires Seattle-based Calistoga Pharmaceuticals
January 2011Gilead acquires Palo Alto, California-based Arresto Biosciences
July 2010Gilead acquires Branford, Connecticut-based CGI Pharmaceuticals
February 2010
The U.S. Food and Drug Administration approves Cayston® (aztreonam for inhalation solution) for the improvement of respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.
April 2009Gilead acquires Palo Alto, California-based CV Therapeutics
August 2008
- The U.S. Food and Drug Administration approves Viread® (tenofovir disoproxil fumarate) for chronic hepatitis B in adults.
April 2008
- The European Commission approves Viread® (tenofovir disoproxil fumarate) for chronic hepatitis B.
November 2007
- Gilead LG Life Sciences, Ltd. enter into an exclusive license agreement focused on the development of caspase inhibitors for the treatment of fibrotic diseases.
October 2007
- Gilead submits regulatory applications for Viread for the potential treatment of chronic hepatitis B to U.S., European Union, Turkey, Australia and New Zealand regulatory authorities.
- Atripla approved by Health Canada.
August 2007
- Acquired Cork, Ireland manufacturing facility from Nycomed
June 2007
|
- The U.S. FDA approves Letairis® (ambrisentan) for the treatment of pulmonary arterial hypertension.
|
May 2007
- Gilead’s Board of Directors approves a two-for-one stock split.
November 2006
- Gilead acquires Edmonton, Alberta-based Raylo Chemicals.
- Gilead acquires Westminster, Colorado-based Myogen Inc.
August 2006
- Gilead acquires Seattle, Washington-based Corus Pharma.
- Gilead announces licensing agreements with India-based companies for manufacturing and distribution of generic versions of Viread ® in the developing world.
July 2006
- The U.S. FDA approves Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) -- the first once-daily single tablet regimen for adults with HIV-1 infection.
March 2005
- Gilead expands its Access Program to include additional countries in the Caribbean and Latin America, meaning that 97 countries, representing an estimated 70 percent of the global HIV/AIDS epidemic, are now included in the company’s access effort.
- Gilead establishes non-profit Foundation, with a mission of improving access to healthcare for people around the world.
February 2005
- European Medicines Agency approves Truvada for the treatment of HIV in the European Union.
December 2004
- The U.S. FDA approves Macugen® for age-related macular degeneration (formerly known as NX 1838).
September 2004
- Gilead's Board of Directors approves a two-for-one stock split.
August 2004
June 2004
- Gilead Sciences is added to the S&P 500.
October 2003
- Emtriva is approved in the European Union for the treatment of HIV/AIDS.
July 2003
- The U.S. FDA approves Emtriva® (emtricitabine) for the treatment of HIV.
April 2003
- Gilead launches its Access Program to provide the anti-HIV therapy Viread® in 68 developing countries at significantly reduced prices.
March 2003
- Hepsera is approved in the European Union for the treatment of chronic hepatitis B.
January 2003
- Gilead acquires Durham, North Carolina-based Triangle Pharmaceuticals.
September 2002
- The U.S. FDA approves Hepsera® (adefovir dipivoxil) for the treatment of chronic hepatitis B.
February 2002
- Gilead's Board of Directors approves a two-for-one stock split.
- European Medicines Agency approves Viread for the treatment of HIV infection in the European Union.
January 2002
- Gilead reports first year of positive cash flow from operations.
December 2001
- OSI Pharmaceuticals acquires oncology assets from Gilead.
October 2001
- The U.S. FDA approves Viread® (tenofovir disoproxil fumarate) for the treatment of HIV infection.
February 2001
- Gilead's Board of Directors approves a two-for-one stock split.
March 2000
- The U.S. FDA approves AmBisome® for the treatment of cryptococcal meningitis in HIV-infected patients.
October 1999
- The U.S. FDA approves Tamiflu® (oseltamivir phosphate) for the treatment of influenza A and B in adults.
July 1999
- Gilead acquires Boulder, Colorado-based NeXstar Pharmaceuticals, Inc. and establishes international operations.
June 1996
- The U.S. FDA approves Vistide® (cidofovir injection) for treatment of CMV retinitis in patients with AIDS.
January 1992
- Gilead completes its initial public offering of 5.75 million shares of Common Stock, for total proceeds of $86.25 million.
November 1991
- Gilead in-licenses nucleotides from IOCB/Rega.
December 1990
- AmBisome® (amphotericin B) liposome for injection receives first approval in Europe for the treatment of severe fungal infections.
June 1987
- Gilead Sciences is founded.
|
|
